Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accelerated approval Phase IV commitments

Executive Summary

FDA's Oncologic Drugs Advisory Committee will meet Nov. 8 to review unfulfilled Phase IV commitments of accelerated approval oncologic drug products. The committee will "identify difficulties associated with completion" of the commitments and provide "advice to sponsors to assist in the planning and execution of postmarketing commitments of newly approved drugs," FDA says. The status of Phase IV commitments for Johnson & Johnson/Alza's Doxil, MedImmune's Ethyol, Ligand/Seragen's Ontak, SkyePharma's DepoCyt, Pfizer's Celebrex, Wyeth's Mylotarg, and Genzyme/Ilex' Campath will be reviewed. Office of Oncology Drugs Director Richard Pazdur said there would be a meeting on the topic during the Sept. 14 review of GlaxoSmithKline's Arranon (1"The Pink Sheet" Sept. 26, 2005, p. 27). The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at at 8 a.m.[Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com]...
Advertisement

Related Content

Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials
Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS046396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel